- â (2015). Arzneimittelrichtgrössen: Ãrzte sollen angstfrei verordnen. Deutsches Ãrzteblatt, 112 (33-34), A1357âA1360.
Paper not yet in RePEc: Add citation now
- â and LâHour, J. (2021). A penalized synthetic control estimator for disaggregated data. Journal of the American Statistical Association (Forthcoming).
Paper not yet in RePEc: Add citation now
â and Nicholson, S. (2009). The formation and evolution of physician treatment styles: An application to cesarean sections. Journal of Health Economics, 28 (6), 1126â1140.
- â, â and â (2015). Comparative politics and the synthetic control method. American Journal of Political Science, 59 (2), 495â510.
Paper not yet in RePEc: Add citation now
â, Diamond, A. and Hainmueller, J. (2010). Synthetic control methods for comparative case studies: Estimating the effect of Californiaâs tobacco control program. Journal of the American Statistical Association, 105 (490), 493â505.
Abadie, A. (2021). Using synthetic controls: Feasibility, data requirements, and methodological aspects. Journal of Economic Literature, 59 (2), 391â425.
Agha, L. and Zeltzer, D. (2019). Drug Diffusion Through Peer Networks: The Influence of Industry Payments. Working Paper 26338, National Bureau of Economic Research.
Avdic, D., Propper, C. and von Hinke, S. (2019). Information shocks and provider responsiveness: evidence from interventional cardiology. CEPR Discussion Paper No. DP13627, Centre for Economic Policy Research.
Baker, L. C. and Phibbs, C. S. (2002). Managed care, technology adoption, and health care: The adoption of neonatal intensive care. RAND Journal of Economics, 33 (3), 524â548.
Berndt, E. R., Gibbons, R. S., Kolotilin, A. and Taub, A. L. (2015). The heterogeneity of concentrated prescribing behavior: Theory and evidence from antipsychotics. Journal of Health Economics, 40, 26â39.
- Blümel, M., Spranger, A., Achstetter, K., Maresso, A. and Busse, R. (2020). Germany: Health system review. Health Systems in Transition, 22 (6), 1â272.
Paper not yet in RePEc: Add citation now
Blankart, K. E. and Arndt, F. (2020). Physician-level cost control measures and regional variation of biosimilar utilization in Germany. International Journal of Environmental Research and Public Health, 17 (11), 4113.
- Bradford, R. H., Shear, C. L., Chremos, A. N., Dujovne, C., Downton, M., Franklin, F. A., Gould, A. L., Hesney, M., Higgins, J. and Hurley, D. P. (1991). Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Archives of Internal Medicine, 151 (1), 43â49.
Paper not yet in RePEc: Add citation now
Buchmueller, T. C., Carey, C. M. and Meille, G. (2020). How well do doctors know their patients? Evidence from a mandatory access prescription drug monitoring program. Health Economics, 29 (9), 957â974.
- Bundesärztekammer, Kassenärztliche Bundesvereinigung, Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (BÃK/KBV/AWMF) (2013). Nationale VersorgungsLeitlinie Chronische KHK â Langfassung, 2. Auflage. Version 1. 2013. Technical report. Available from: http://www.khk.versorgungsleitlinien.de.
Paper not yet in RePEc: Add citation now
- Cardinal, L. B., Kreutzer, M. and Miller, C. C. (2017). An aspirational view of organizational control research: Re-invigorating empirical work to better meet the challenges of 21st century organizations. Academy of Management Annals, 11 (2), 559â592.
Paper not yet in RePEc: Add citation now
Chandra, A., Cutler, D. and Song, Z. (2011). Who ordered that? The economics of treatment choices in medical care. In Handbook of Health Economics, vol. 2, Elsevier, pp. 397â432.
Currie, J. M. and MacLeod, W. B. (2020). Understanding doctor decision making: The case of depression treatment. Econometrica, 88 (3), 847â878.
Currie, J., MacLeod, W. B. and Van Parys, J. (2016). Provider practice style and patient health outcomes: The case of heart attacks. Journal of Health Economics, 47, 64â80.
Cutler, D., Skinner, J. S., Stern, A. D. and Wennberg, D. (2019). Physician beliefs and patient preferences: A new look at regional variation in health care spending. American Economic Journal: Economic Policy, 11 (1), 192â221.
Depalo, D., Bhattacharya, J., Atella, V. and Belotti, F. (2019). When technological advance meets physician learning in drug prescribing. Working Paper 26202, National Bureau of Economic Research.
Dillender, M. (2018). What happens when the insurer can say no? Assessing prior authorization as a tool to prevent high-risk prescriptions and to lower costs. Journal of Public Economics, 165, 170â200.
- Dulleck, U. and Kerschbamer, R. (2006). On doctors, mechanics, and computer specialists: The economics of credence goods. Journal of Economic Literature, 44 (1), 5â42.
Paper not yet in RePEc: Add citation now
Ellis, R. P. and McGuire, T. G. (1986). Provider behavior under prospective reimbursement: Cost sharing and supply. Journal of Health Economics, 5 (2), 129â151.
- Elshaug, A. G., Rosenthal, M. B., Lavis, J. N., Brownlee, S., Schmidt, H., Nagpal, S., Littlejohns, P., Srivastava, D., Tunis, S. and Saini, V. (2017). Levers for addressing medical underuse and overuse: achieving high-value health care. The Lancet, 390 (10090), 191â202.
Paper not yet in RePEc: Add citation now
Epstein, A. J. and Ketcham, J. D. (2014). Information technology and agency in physiciansâ prescribing decisions. The RAND Journal of Economics, 45 (2), 422â448.
Escarce, J. (1996). Externalities in hospitals and physician adoption of a new surgical technology: An exploratory analysis. Journal of Health Economics, 15 (6), 715â734.
Finkelstein, A., Gentzkow, M. and Williams, H. (2016). Sources of geographic variation in health care: Evidence from patient migration. The Quarterly Journal of Economics, 131 (4), 1681â1726.
Fischer, K. E., Koch, T., Kostev, K. and Stargardt, T. (2018). The impact of physician-level drug budgets on prescribing behavior. The European Journal of Health Economics, 19 (2), 213â222.
Frank, R. G. and Zeckhauser, R. J. (2007). Custom-made versus ready-towear treatments: Behavioral propensities in physiciansâ choices. Journal of Health Economics, 26 (6), 1101â1127.
- Gehlbach, S. H., Wilkinson, W. E., Hammond, W. E., Clapp, N. E., Finn, A. L., Taylor, W. J. and Rodell, M. (1984). Improving drug prescribing in a primary care practice. Medical Care, 22 (3), 193â201.
Paper not yet in RePEc: Add citation now
- Goldman, D. P., Joyce, G. F. and Zheng, Y. (2007). Prescription drug cost sharing: Associations with medication and medical utilization and spending and health. JAMA, 298 (1), 61â69.
Paper not yet in RePEc: Add citation now
Grytten, J. and Sørensen, R. (2003). Practice variation and physician-specific effects. Journal of Health Economics, 22 (3), 403â418.
- Howell, S., Yin, P. T. and Robinson, J. C. (2021). Quantifying the economic burden of drug utilization management on payers, manufacturers, physicians, and patients. Health Affairs, 40 (8), 1206â1214.
Paper not yet in RePEc: Add citation now
Iizuka, T. (2007). Expertsâ agency problems: evidence from the prescription drug market in Japan. The RAND Journal of Economics, 38 (3), 844â862.
Imbens, G. W. and Wooldridge, J. M. (2009). Recent developments in the econometrics of program evaluation. Journal of Economic Literature, 47 (1), 5â 86.
- Ivers, N., Jamtvedt, G., Flottorp, S., Young, J. M., Odgaard-Jensen, J., French, S. D., OâBrien, M. A., Johansen, M., Grimshaw, J. and Oxman, A. D. (2012). Audit and feedback: Effects on professional practice and healthcare outcomes. The Cochrane Database of Systematic Reviews, (6), CD000259.
Paper not yet in RePEc: Add citation now
- Jackevicius, C. A., Chou, M. M., Ross, J. S., Shah, N. D. and Krumholz, H. M. (2012). Generic Atorvastatin and Health Care Costs. The New England Journal of Medicine, 366 (3), 201â204.
Paper not yet in RePEc: Add citation now
Janakiraman, R., Dutta, S., Sismeiro, C. and Stern, P. (2008). Physiciansâ persistence and its implications for their response to promotion of prescription drugs. Management Science, 54 (6), 1080â1093.
- Jones, P. H., Davidson, M. H., Stein, E. A., Bays, H. E., McKenney, J. M., Miller, E., Cain, V. A. and Blasetto, J. W. (2003). Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR trial). The American Journal of Cardiology, 92 (2), 152â160.
Paper not yet in RePEc: Add citation now
- Jones, P., Kafonek, S., Laurora, I. and Hunninghake, D. (1998). Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). The American Journal of Cardiology, 81 (5), 582â587.
Paper not yet in RePEc: Add citation now
- Ketcham, J. D. and Epstein, A. J. (2008). Medicaid preferred drug listsâ costs to physicians. Medical Care, 46 (1), 9â16.
Paper not yet in RePEc: Add citation now
- Klose, G. and Schwabe, U. (2015). Lipidsenkende Mittel. In U. Schwabe and D. Paffrath (eds.), Arzneiverordnungs-Report 2015, Berlin, Heidelberg: Springer Berlin Heidelberg, pp. 745â756.
Paper not yet in RePEc: Add citation now
- Korzilius, H. (2011). Kein Arzt wir für seine teuren Patienten bestraft. Deutsches Ãrzteblatt, 108 (18), A984âA986.
Paper not yet in RePEc: Add citation now
- Miraldo, M., Hauck, K., Vernet, A. and Wheelock, A. (2019). Variations in the adoption of healthcare innovation: A literature review. Oxford Research Encyclopedia of Economics and Finance.
Paper not yet in RePEc: Add citation now
Molitor, D. (2018). The evolution of physician practice styles: Evidence from cardiologist migration. American Economic Journal: Economic Policy, 10 (1), 326â56.
- Naci, H., Brugts, J. and Ades, T. (2013). Comparative tolerability and harms of individual statins. Circulation: Cardiovascular Quality and Outcomes, 6 (4), 390â399.
Paper not yet in RePEc: Add citation now
- Ofori-Asenso, R., Ilomaki, J., Tacey, M., Zomer, E., Curtis, A. J., Si, S., Zullo, A. R., Korhonen, M. J., Bell, J. S., Zoungas, S. and Liew, D. (2018). Switching, discontinuation, and reinitiation of statins among older adults.
Paper not yet in RePEc: Add citation now
- Raelin, J. A. (2011). The end of managerial control? Group & Organization Management, 36 (2), 135â160.
Paper not yet in RePEc: Add citation now
- Reiner, Ž., Catapano, A. L., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P. et al. (2011). ESC/EAS guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). European Heart Journal, 32 (14), 1769â1818.
Paper not yet in RePEc: Add citation now
- Robert Koch-Institut (Hrsg) (RKI) (2015). Gesundheit in Deutschland. Gesundheitsberichterstattung des Bundes. Gemeinsam getragen von RKI und Destatis. Technical report, RKI, Berlin.
Paper not yet in RePEc: Add citation now
Rubin, D. B. (2005). Causal inference using potential outcomes: Design, modeling, decisions. Journal of the American Statistical Association, 100 (469), 322â331.
- Sacarny, A., Yokum, D., Finkelstein, A. and Agrawal, S. (2016). Medicare letters to curb overprescribing of controlled substances had no detectable effect on providers. Health Affairs, 35 (3), 471â479.
Paper not yet in RePEc: Add citation now
- Saito, Y., Yamada, N., Teramoto, T., Itakura, H., Hata, Y., Nakaya, N., Mabuchi, H., Tushima, M., Sasaki, J., Ogawa, N. and Goto, Y. (2002). A randomized, double-blind trial comparing the efficacy and safety of pitavastatin versus pravastatin in patients with primary hypercholesterolemia. Atherosclerosis, 162 (2), 373â379.
Paper not yet in RePEc: Add citation now
- Schwabe, U. (2006). Arzneiverordnungen 2005 im überblick. In U. Schwabe and D. Paffrath (eds.), Arzneiverordnungs-Report 2006, Springer, pp. 3â46.
Paper not yet in RePEc: Add citation now
Skinner, J. and Staiger, D. (2015). Technology diffusion and productivity growth in health care. Review of Economics and Statistics, 97 (5), 951â964.
Stargardt, T. (2010). The impact of reference pricing on switching behaviour and healthcare utilisation: the case of statins in Germany. The European Journal of Health Economics, 11 (3), 267â277.